Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

View:
Post by cheetio on Apr 19, 2015 8:23am

update

Status Update! On Friday, April 10, 2015, status on the IMVYON trademark changed to PUBLICATION/ISSUE REVIEW COMPLETE. https://www.trademarkia.mx/company-telesta-therapeutics-inc-4250153-page-1-1
Comment by account15 on Apr 19, 2015 10:16am
nice find. thank you
Comment by CasusFortuitus on Apr 20, 2015 7:01am
INVYON.COM is also one of the Bioniche/Telesta web domains. Here's a partial list according to Whoisology.com: celoxveterinary.com bionichebotanicals.com bionichenews.com onkalta.com horsewound.com bionichelifesciences.com bioniche.com bio-iso-g.com ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities